-
Results from the LAUREL trial showed that despite nominally significant benefits with etrolizumab, endoscopic remission and histologic remission was not met in a cohort of TNF-naïve ulcerative colitis patients.
-
Filgotinib was effective and well-tolerated as maintenance treatment for patients with moderately to severely active ulcerative colitis who had achieved a clinical response to induction treatment with this drug.
-
Weekly dupilumab demonstrated significant and clinically meaningful improvements in histologic, symptomatic, endoscopic, and molecular aspects of eosinophilic esophagitis (EoE).
-
Hackers use the ransomware technique to block a computer network and demand a ransom to restore access to it. A first (indirect) death caused by such an attack occurred in a German hospital.
-
An analysis of an Australian tertiary health network showed a significant improvement in overall sessile serrated adenoma detection rate (SSADR) over a 4-year period.
-
Post-colonoscopy colorectal cancers accounted for a substantial proportion of all IBD-related colorectal cancers. However, IBD patients had a low absolute risk of post-colonoscopy colorectal cancers.
-
Mirikizumab demonstrated sustained efficacy at week 52 in patients with moderate-to-severe Crohn’s disease. In the maintenance period of the phase 2 SERENITY trial, few patients discontinued due to adverse events.
-
A Japanese study showed that the presence or absence of cholecystectomy does not affect biliary tract problems or mortality in patients ≥80 years old. Follow-up may be appropriate, without surgery.
-
The uroguanylin-analog plecanatide is an effective symptomatic treatment for patients with IBS-C. An early clinical response appeared to be predictive of overall response after 12 weeks.
-
TNF antagonists do not appear to be associated with severe COVID-19, a large, international registry to monitor outcomes of IBD patients with confirmed COVID-19 found.
-
High-quality therapeutic ERCP, EUS, luminal stenting, and dilatation, can be delivered safely to appropriately prioritized patients during the COVID-19 pandemic.
-
The SARS-CoV-2 vaccine race meets the US presidential race, turning vaccine development into a political propaganda topic and pushing pharma companies to publish ongoing trial protocols for transparency.
-
STARDUST is the first randomized treat-to-target trial using endoscopy at week 16 to guide dose escalation in Crohn’s disease patients. T2T could be an additional tool for ustekinumab dosing decisions.
-
Sports are key for this patient group. Hypoglycemia should be avoided by supplementing carbohydrate intake, preprandial and basal insulin doses reduction, and combining aerobic exercise with other activities.
-
Oncological treatment with PD1 or PD-L1 inhibitors can trigger type 1 diabetes. This undesirable effect usually occurs early, often accompanied by acute ketoacidosis. Current data on the issue were presented.
-
People who suffer from diabetes mellitus and have elevated uric acid levels, often also have diabetic nephropathy. The question was clearly answered: uric acid is a biomarker and not a risk factor.
-
Hypoglycemia in diabetes types 1 and 2 patients has not decreased in recent years despite numerous improvements. The role of C-peptide in hypoglycemia and modern techniques to prevent it were discussed.
-
This story highlights the shortcomings of the scientific publication system. At a time when studies are unveiled on social networks, collaborative reviewing must be strengthened and expanded.
-
Dapagliflozin reduced kidney failure risk in patients with CKD, the risk of cardiovascular death or hospitalization due to heart failure, and the SGLT2 inhibitor prolonged survival.
-
Björn Eliasson presented non-insulin-containing therapies, such as dapagliflozin, while Eelco de Koning discussed the pros and cons of pancreatic and beta-cell transplantation.
